During 2025, the Company reduced its workforce by approximately 27% of full-time employees to align its resources with its ongoing clinical and preclinical programs. There was no expense related to the workforce reduction incurred during the three months ended June 30, 2026 and 2025.

The following table summarizes the accrued liabilities activity recorded in connection with the reduction in workforce for the six months ended June 30, 2026:


(in thousands)	Amount accrued at December 31, 2025		Charges		Amount Paid			Adjustments		Amount accrued at June 30, 2026
Workforce reduction	$	711	$	—	$	(711	)	$	—	$	—